Prime Medicine, Inc. (PRME) Return on equity 2020–2025
Prime Medicine, Inc. (PRME) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-166.4%FY2025 · since FY2020: -145.9% → -166.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -166.4% | -38.5 pp |
| FY2024 | -127.9% | +21.0 pp |
| FY2023 | -148.9% | -110.4 pp |
| FY2022 | -38.5% | — |
| FY2020 | -145.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More PRME financial trends
PRME RevenuePRME Net incomePRME Net marginPRME Gross profitPRME Gross marginPRME Operating incomePRME Operating marginPRME Operating cash flowPRME Free cash flowPRME Capital expendituresPRME Stock buybacksPRME Dividends paidPRME Total assetsPRME Total liabilitiesPRME Shareholders’ equityPRME overview →